Clinical Trials Directory

Trials / Completed

CompletedNCT00294398

Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
152 (actual)
Sponsor
Children's Hospital of Philadelphia · Academic / Other
Sex
All
Age
1 Year – 18 Years
Healthy volunteers
Not accepted

Summary

Specific Aim: To determine whether a prescription for Inhaled Corticosteroids (ICS) added to standard Emergency Department (ED) discharge therapy for young children with persistent asthma symptoms increases ICS use and improves symptoms and quality of life over the months following the ED visit. Hypotheses: In a cohort of pediatric patients with persistent asthma discharged from the ED after an acute asthma exacerbation, a prescription for ICS will: 1. Improve usage of ICS as measured by refill of a prescription within the first 2 months after the ED visit 2. Improve symptom severity at two weeks after an ED visit as measured by days of cough, wheeze, missed school, daycare or work 3. Improve patient and caregiver asthma-related quality of life during the 2 months following an ED visit measured by asthma Health Related Quality of Life (HRQL) 4. Improve asthma control at 2 months as measured by a validated asthma instrument

Detailed description

Abstract. Background: Asthma prevalence, emergency visits, and hospitalizations have increased substantially, especially among young children and urban populations. Although inhaled corticosteroids (ICS) are the mainstay of treatment for persistent asthma, studies have demonstrated a low rate of ICS usage and primary care provider follow-up within a month of an Emergency Department (ED) visit. Furthermore, ICS usage and adherence with National Asthma Education and Prevention Program (NAEPP) recommendations is low even for children that follow-up with their primary care physician (PCP). In addition, other studies have demonstrated frequent symptoms, activity restriction, and missed school or work during the weeks following an ED visit. Prescribing ICS at ED discharge occurs uncommonly in the United States based on surveys and reviews of current practice. Adult studies have been inconclusive and the role of ICS after a pediatric emergency visit for asthma has not been studied. This study will assess the short-term outcomes of prescribing ICS to young children with persistent asthma symptoms after an emergency visit for asthma. Objective: To determine whether a prescription for ICS added to standard asthma ED discharge therapy to young children with persistent asthma increases adherence to NAEPP guidelines for ICS usage at 2 months follow up and improves short-term symptoms and quality of life for patient and caregiver. Methods: Randomized control trial of children 1- 8yo of age with persistent asthma being discharged after an emergency visit for asthma. Subjects will be randomized to receive standard therapy of oral corticosteroid, albuterol, and education versus standard care plus a prescription for budesonide once daily. A questionnaire will be administered at baseline, with follow-up telephone interviews conducted at 2 weeks and 2 months. Pharmacy verification of refill of a second prescription of ICS will be the primary outcome. Asthma symptoms and quality of life will be assessed as secondary outcomes.

Conditions

Interventions

TypeNameDescription
OTHERICS Prescription + Standard Asthma ED Discharge TherapySubjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age: 1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily
OTHERStandard Asthma ED Discharge TherapySubjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.

Timeline

Start date
2006-03-01
Primary completion
2009-11-01
Completion
2009-11-01
First posted
2006-02-22
Last updated
2015-05-13
Results posted
2015-04-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00294398. Inclusion in this directory is not an endorsement.